Healthcare Stocks Are on Fire -- Don't Miss These Opportunities
Innovation, regulatory policy, and demographics are driving healthcare stocks higher. Healthcare companies have also posted strong first-quarter results.
MRK - Merck & Co., Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$129.31
DETAILS
HIGH:
$150.00
LOW:
$100.00
MEDIAN:
$133.00
CONSENSUS:
$129.31
UPSIDE:
5.64%
Stock News
Merck stock jumps as Keytruda combo trials boost cancer pipeline
Shares of Merck & Co. (MRK) rose 5% on Friday after the pharmaceutical giant reported positive developments across multiple oncology programs, reinforcing investor confidence in its efforts to extend the dominance of blockbuster cancer drug Keytruda ahead of looming patent expirations later this decade. The rally followed encouraging Phase 3 clinical trial results involving sacituzumab tirumotecan, or sac-TMT, an antibody-drug conjugate developed in partnership with Sichuan Kelun-Biotech Biopharmaceutical.
Will Weak Gardasil Sales Continue to Ail MRK's Vaccines Sales in 2026?
Merck's Gardasil sales plunge as weak China demand, inventory issues and softer Japan trends cloud the vaccine's overall growth outlook in 2026.
Pharma Stock Pops On European Seal of Approval
Merck (NYSE:MRK) stock is up 5% to trade at $121.75, after the blue-chip pharma giant received the "go ahead" from European officials in regard to its combination of the company's products, Keytruda and Padcev, for a lower risk form of bladder cancer treatment.
Merck Stock Climbs on Cancer Data. Why the Drugmaker Is More Than a One-Trick Pony.
Merck shares rose after partner Kelun-Biotech reported positive late-stage trial results for a Keytruda combination treatment in lung cancer.
Merck Stock Zooms Closer To A Breakout On 'A New Chapter' In Cancer
Merck stock popped early Friday after European officials recommended approving its combination for a form of bladder cancer.
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with Padcev® (enfortumab vedotin-ejfv), an antibody-drug conjugate (ADC), as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment, for ad.
Kelun, Merck's lung cancer combo improves survival in late-stage China trial
Sichuan Kelun-Biotech Biopharmaceutical said on Thursday its experimental treatment combined with partner Merck's Keytruda improved survival rate in patients with advanced lung cancer, meeting the main goal of a late-stage study.
Moderna, Merck cancer combo cuts melanoma spread risk at five years
Moderna and Merck's combination therapy for skin cancer helped reduce risk of cancer spreading to another part of the body by 59% after five years of follow-up, data from a mid-stage trial showed Thursday.
Eli Lilly vs. Merck: Which Pharma Stock Looks Stronger Now?
LLY's booming GLP-1 franchise and expanding pipeline strengthen its edge over Merck despite rising competition and pricing pressure.
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer
DARMSTADT, Germany--(BUSINESS WIRE)--Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer.
EXEL Collaborates With MRK for Late-Stage Colorectal Cancer Study
Exelixis teams up with Merck to advance zanzalintinib in a phase III colorectal cancer study, expanding its pipeline beyond Cabometyx.
National Advertising Review Board Refers Merck Animal Health to FTC and FDA for Bravecto Quantum Dosing Claims
A panel of the National Advertising Review Board (NARB), the appellate advertising body of BBB National Programs, has referred Intervet, Inc. (d/b/a Merck Animal Health) to the Federal Trade Commission (FTC) and the Food and Drug Administration (FDA) for failure to comply with its recommendation to discontinue or modify express once-a-year dosing claims for its Bravecto® Quantum injectable flea and tick treatment for dogs. A panel of the National Advertising Review Board (NARB), the appellate advertising body of BBB National Programs, has referred Intervet, Inc. (d/b/a Merck Animal Health) to the Federal Trade Commission (FTC) and the Food and Drug Administration (FDA) for failure to comply with its recommendation to discontinue or modify express once-a-year dosing claims for its Bravecto® Quantum injectable flea and tick treatment for dogs.
Merck's ADC Candidate Meets Goals in Endometrial Cancer Study
MRK's investigational TROP2-directed ADC, sac-TMT, achieves key survival goals in a phase III endometrial cancer study.
7 Healthcare AI Stocks Under $50 With Huge Upside Potential
Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing.
Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck's Keytruda
A late-stage trial evaluating Regeneron's fianlimab, a skin cancer drug, fails to meet its primary endpoint.
Merck's endometrial cancer drug meets late-stage trial goals
Merck said on Monday its experimental endometrial cancer drug met the main goals of a late-stage trial.
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's TroFuse-005 Trial Evaluating Sac-TMT Met Primary Endpoints of OS and PFS in Certain Patients With Advanced or Recurrent Endometrial Cancer.
Why Is Regeneron Stock Sinking Monday?
Regeneron melanoma combo trial missed its main goal against Keytruda despite longer progression-free survival in the high-dose arm.
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
Price Targets
Merck price target raised to $112 from $109 at Morgan Stanley
$112.00
(was $112.47)
Terence Flynn
·
Morgan Stanley
Merck (MRK) PT Raised to $150 at Wells Fargo
$150.00
(was $116.22)
Mohit Bansal
·
Wells Fargo
RBC Capital Starts Merck (MRK) at Outperform
$142.00
(was $123.93)
Trung Huynh
·
RBC Capital
Merck upgraded to Buy from Hold at Deutsche Bank
$150.00
(was $121.53)
James Shin
·
Deutsche Bank
Merck price target raised to $133 from $120 at Goldman Sachs
$133.00
(was $115.86)
Asad Haider
·
Goldman Sachs
Merck price target raised to $135 from $130 at BMO Capital
$135.00
(was $115.86)
BMO Capital
Merck price target raised to $100 from $95 at Bernstein
$100.00
(was $115.86)
Bernstein
Merck price target raised to $136 from $120 at Scotiabank
$136.00
(was $116.37)
Scotiabank
Merck price target raised to $116 from $83 at Cantor Fitzgerald
$116.00
(was $107.40)
Cantor Fitzgerald
Merck upgraded to Outperform from Peer Perform at Wolfe Research
$135.00
(was $108.59)
Wolfe Research
Merck price target raised to $130 from $105 at UBS
$130.00
(was $110.96)
UBS
Merck upgraded to Outperform from Market Perform at BMO Capital
$130.00
(was $99.21)
BMO Capital
Merck price target raised to $102 from $100 at Morgan Stanley
$102.00
(was $100.06)
Morgan Stanley
Merck price target raised to $120 from $100 at HSBC
$120.00
(was $96.89)
Rajesh Kumar
·
HSBC
Merck price target raised to $122 from $104 at Guggenheim
$122.00
(was $100.89)
Guggenheim
Merck price target raised to $120 from $105 at Scotiabank
$120.00
(was $101.88)
Louise Chen
·
Scotiabank
Merck price target raised to $120 from $92 at Goldman Sachs
$120.00
(was $101.83)
Asad Haider
·
Goldman Sachs
Merck price target raised to $100 from $98 at Morgan Stanley
$100.00
(was $84.65)
Terence Flynn
·
Morgan Stanley
Merck downgraded to Hold from Buy at Berenberg
$90.00
(was $81.14)
Luisa Hector
·
Berenberg Bank
Merck price target lowered to $98 from $99 at Morgan Stanley
$98.00
(was $84.39)
Terence Flynn
·
Morgan Stanley